TAOYUAN, Taiwan, Feb. 22, 2013 /PRNewswire/ -- SHL [http://www.shl-group.com/] announced plans this week to expand production facilities in Taiwan. A leader in the field of drug delivery devices such as auto injectors and pen injectors, SHL has continued to invest heavily in facilities, advanced machinery and R&D. With the rapid growth of the biologic injectable market, device suppliers are under pressure to broaden the range of services that they can provide. SHL has responded by making significant capital investments such as the 40 Million USD that will be spent this year alone.
(Photo: http://photos.prnewswire.com/prnh/20130222/HK63940 [http://photos.prnewswire.com/prnh/20130222/HK63940] )
CEO Roger Samuelsson commented, "Five years ago I signed a letter of intent with the Taiwan government promising to invest 100 Million USD here. We kept our promise and even completed that investment early. Now we will spend another 40 Million USD for 2013. Our auto injector business is one of the key drivers to this expansion of production capacity. Our customers are bringing more biologics to market and SHL is going to ensure that we meet their needs."
This year SHL will invest primarily in molding, material handling, assembly and automation capabilities. Production will be ramped up at several facilities in Taiwan, Taoyuan One and various NanKan sites. Increased capacity will allow SHL the flexibility to provide higher quantities of devices each month. In addition to auto injectors, SHL produces pen injectors, infusors and inhaler systems. The company now has well over 2,200 staff globally and will be hiring several hundred new employees in Taiwan this year.
SHL is the world's largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 2,200 staff globally, with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.
SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of "next generation" drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of several distinct group companies:
-- SHL MedicalDesigns, develops and manufactures advanced drug delivery
devices for leading pharmaceutical and biotech companies
-- SHL HealthcareDevelops and manufactures equipment solutions for home,
hospital and long term care use SHL Technologies
-- Provides contract manufacturing and engineering services for the
production of complex medtech and industrial products
-- SHL Pharma Provides final assembly, labeling and packaging services of
drug delivery devices to the pharmaceutical and biotechnology industries
For additional information visit www.shl-group.com [http://www.shl-group.com/] or contact us at email@example.com [mailto:firstname.lastname@example.org]
SHL Media Contact
Steven R. Kaufman
Web site: http://www.shl-group.com/